MOMETASONE FUROATE solution United States - English - NLM (National Library of Medicine)

mometasone furoate solution

padagis israel pharmaceuticals ltd - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 ml - mometasone furoate topical solution 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. mometasone furoate topical solution, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate topical solution 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by l

MOMETASONE FUROATE ointment United States - English - NLM (National Library of Medicine)

mometasone furoate ointment

padagis israel pharmaceuticals ltd - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 g - mometasone furoate ointment, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. mometasone furoate ointment, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate ointment, 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/

MOMETASONE FUROATE cream United States - English - NLM (National Library of Medicine)

mometasone furoate cream

padagis israel pharmaceuticals ltd - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 g - mometasone furoate cream usp, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. mometasone furoate cream is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights

MOMETASONE FUROATE - mometasone furoate solution United States - English - NLM (National Library of Medicine)

mometasone furoate - mometasone furoate solution

harris pharmaceutical, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 ml - mometasone furoate topical solution usp, 0.1% (lotion) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. none. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate topical solution usp, 0.1% (lotion) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. mometasone furoate also caused dysto

MOMETASONE FUROATE ointment United States - English - NLM (National Library of Medicine)

mometasone furoate ointment

cosette pharmaceuticals, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 g - mometasone furoate, usp ointment 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. mometasone furoate, usp ointment 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate, usp ointment 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produce

MOMETASONE FUROATE cream United States - English - NLM (National Library of Medicine)

mometasone furoate cream

cosette pharmaceuticals, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 g - mometasone furoate cream, usp, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. mometasone furoate cream, usp, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate cream, usp, 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malf

MOMETASONE FUROATE solution United States - English - NLM (National Library of Medicine)

mometasone furoate solution

cosette pharmaceuticals, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 ml - mometasone furoate topical solution usp, 0.1% (lotion) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. mometasone furoate topical solution usp, 0.1% (lotion) is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate topical solution usp, 0.1% (lotion) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and

MOMETASONE FUROATE solution United States - English - NLM (National Library of Medicine)

mometasone furoate solution

e. fougera & co. a division of fougera pharmaceuticals inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 ml - mometasone furoate lotion (mometasone furoate topical solution 0.1%) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. mometasone furoate lotion (mometasone furoate topical solution 0.1%) is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects, pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate lotion (mometasone furoate topical solution 0.1%) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometas

mometasone furoate- mometasone furoate lotion United States - English - NLM (National Library of Medicine)

mometasone furoate- mometasone furoate lotion

warrick pharmaceuticals corporation - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - lotion - 1 mg in 1 ml - mometasone furoate lotion 0.1% (mometasone furoate topical solution usp) is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. since safety and efficacy of mometasone furoate lotion 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended, (see precautions – pediatric use ). mometasone furoate lotion 0.1% (mometasone furoate topical solution usp) is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.

MOMETASONE FUROATE ointment United States - English - NLM (National Library of Medicine)

mometasone furoate ointment

torrent pharmaceuticals limited - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older.           mometasone furoate ointment is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, a